Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Jun;1(1):20-8.
doi: 10.1586/14737140.1.1.20.

Thalidomide in the treatment of multiple myeloma

S V Rajkumar  1
Affiliations
Review

Thalidomide in the treatment of multiple myeloma

S V Rajkumar. Expert Rev Anticancer Ther. 2001 Jun.

Abstract

Thalidomide--banned from clinical use in the 1960s because of severe teratogenicity--is now back in clinical practice as an effective agent in the treatment of relapsed and refractory multiple myeloma. Several clinical trials have determined that thalidomide is active in 25-35% of patients with relapsed myeloma. The role of thalidomide in early-stage myeloma is being actively investigated. Thalidomide has antiangiogenic and immunomodulatory properties and is an effective inhibitor of TNF-alpha. However, the mechanism of its action in myeloma remains unclear. Major toxicities of thalidomide include constipation, sedation, skin rash, fatigue and peripheral neuropathy. This paper summarizes the current status of thalidomide in multiple myeloma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Targeted therapy in melanoma.
    Tawbi H, Nimmagadda N. Tawbi H, et al. Biologics. 2009;3:475-84. doi: 10.2147/btt.2009.3637. Epub 2009 Dec 29. Biologics. 2009. PMID: 20054438 Free PMC article.
  • Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
    Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Lesokhin AM, et al. Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15. Nat Med. 2023. PMID: 37582952 Free PMC article. Clinical Trial.
  • Management of thalidomide toxicity.
    Ghobrial IM, Rajkumar SV. Ghobrial IM, et al. J Support Oncol. 2003 Sep-Oct;1(3):194-205. J Support Oncol. 2003. PMID: 15334875 Free PMC article. Review.

MeSH terms

LinkOut - more resources